⁣ ⁢ Former President Donald Trump is⁣ considering measures that could significantly restrict U.S. access to pharmaceuticals and biotechnology products originating from China, ⁣according‍ to a
⁣
September 10, 2025, report in the New York Times.
The proposed actions ⁢aim to bolster the domestic U.S.‍ biopharmaceutical industry, but face internal debate due to the reliance⁣ on Chinese biotech firms for innovative ‍drug progress.

The proposed Restrictions

The new York Times report details that ⁤the Trump administration⁤ is weighing a range of options, including increased scrutiny of Chinese biotech investments in the U.S., restrictions on the import of certain pharmaceutical ingredients, and potential tariffs on finished drug products. The rationale behind these measures⁣ centers on national ⁢security concerns and a desire to reduce ⁣U.S. dependence ‍on China for critical⁣ medicines.

⁤ ⁣ Specifically, the administration is concerned⁢ about the potential for China to leverage its dominance in pharmaceutical manufacturing to exert political pressure or disrupt‍ the U.S. drug supply. This concern has been⁢ amplified by geopolitical tensions and ongoing trade disputes between the two countries.
‍‍

Industry Reactions:‍ A Divided landscape

Support for the proposed ⁢measures within the biopharmaceutical industry⁣ is far from unanimous. While many U.S. companies ⁣welcome the prospect of increased domestic manufacturing and reduced competition from Chinese firms, others express ⁢concerns about the potential impact on innovation and drug⁣ costs.

⁣ ‍A key point of contention is the role of Chinese biotech⁣ companies in developing cutting-edge therapies. Many U.S. pharmaceutical companies collaborate with Chinese firms on research and development, and rely on them for access to novel technologies and manufacturing capabilities. Restricting access to⁣ these resources could slow down the development of new drugs and increase costs for patients.

⁤ The Pharmaceutical Research and Manufacturers of America (PhRMA), the industry’s leading trade ⁢group, has not yet issued a formal statement on the proposed measures, reflecting the⁤ internal divisions within its membership.

The‍ Growing Role of Chinese Biotech

China⁤ has emerged as a ⁤significant player in the global biotechnology industry over the past decade, driven by considerable government investment and a rapidly growing domestic market.Chinese ⁣biotech companies are⁣ increasingly focused on developing innovative therapies, including gene therapies, cell‍ therapies, and novel⁢ antibody drugs.

According to data from the China Biotechnology Industry Institution (CBIO), investment in Chinese biotech companies reached $30 billion in 2024, a significant increase from $10 billion in⁤ 2019. this growth has⁤ attracted the attention of ‍U.S. pharmaceutical companies, many of whom have established partnerships with Chinese firms.